HedgeChatter

  • Home /
  • Tag Archives

ABIO

ARCA biopharma Files Shelf Registration Statement

[Business Wire] – ARCA biopharma, Inc. , a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has filed a universal shelf registration statement with the Securities and Exchange Commis moreView todays social media effects on ABIOView the latest stocks trending across Twitter. Click to view dashboardSee who ARCA is hiring next, click here to view […]

April 4, 2014 Bystocknews , Comments Off on ARCA biopharma Files Shelf Registration Statement read more

Dan Mitchell Joins ARCA biopharma Board of Directors

[Business Wire] – ARCA biopharma, Inc. , a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that Dan Mitchell has been appointed to the Company’s Board of Directors. moreView todays social media effects on ABIOView the latest stocks trending across Twitter. Click to view dashboardSee who ARCA is hiring next, click here to view […]

February 12, 2014 Bystocknews , Comments Off on Dan Mitchell Joins ARCA biopharma Board of Directors read more

Why Arca Biopharma Is A Buy

moreView todays social media effects on ABIOView the latest stocks trending across Twitter. Click to view dashboard […]

January 14, 2014 Bystocknews , Comments Off on Why Arca Biopharma Is A Buy read more

Most active Nasdaq-traded stocks

moreView todays social media effects on ABIOView the latest stocks trending across Twitter. Click to view dashboard […]

December 9, 2013 Bystocknews , Comments Off on Most active Nasdaq-traded stocks read more

8:32 am ARCA biopharma announces IDE submission to FDA for Gencaro companion diagnostic test; phase 2B/3 GENETIC-AF trial on track to begin patient enrollment in Q1 2014

moreView todays social media effects on ABIOView the latest stocks trending across Twitter. Click to view dashboard […]

December 5, 2013 Bystocknews , Comments Off on 8:32 am ARCA biopharma announces IDE submission to FDA for Gencaro companion diagnostic test; phase 2B/3 GENETIC-AF trial on track to begin patient enrollment in Q1 2014 read more